Results 71 to 80 of about 50,152 (259)
Addiction, EarlyView.Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden +10 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove +3 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Measurement‐based care (MBC) is a structured approach using standardized, repeated assessments to monitor treatment progress and guide clinical decision‐making. MBC improves outcomes for substance use treatment but can be time consuming due in part to lengthy assessment tools. Single‐item, patient‐reported outcome measures (
Thomas J. Reese +13 more
wiley +1 more source
Addiction, EarlyView.Abstract Aim We evaluated whether community‐level naloxone distribution, medication for opioid use disorder treatment and retention and incident high‐risk opioid prescribing rates were associated with opioid overdose death rates. Design Observational cohort conducted using 2019 to 2023 community‐level data as an exploratory analysis of the HEALing ...
Alexander Y. Walley +19 more
wiley +1 more source
Effects of buprenorphine on pain perception in healthy adults: a meta-narrative systematic review
PAIN Reports. The availability of knowledge about the effects of buprenorphine on pain perception in healthy adults could help investigators select experimental tests with evidence of responsiveness to buprenorphine in nondiseased states.
W. Michael Hooten +7 more
doaj +1 more source
Addiction, EarlyView.Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts +2 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw +5 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson +13 more
wiley +1 more source
Substance Abuse and Rehabilitation, 2016 Lynn R Webster,1 Michael Camilleri,2 Andrew Finn3 1PRA Health Sciences, Salt Lake City, UT, 2Mayo Clinic Rochester, MN, 3BioDelivery Sciences, Inc., Raleigh, NC, USA Abstract: Buprenorphine and buprenorphine–naloxone fixed combinations are ...
Webster LR, Camilleri M, Finn A
doaj
Addiction, EarlyView.Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan +13 more
wiley +1 more source